Cargando…

The probability of cost-effectiveness

BACKGROUND: The study of cost-effectiveness comparisons between competing medical interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences between the various approaches can be subtle, and one purpose of this article is to clarify some important distinction...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Hagan, Anthony, Stevens, John W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC100784/
https://www.ncbi.nlm.nih.gov/pubmed/11914138
http://dx.doi.org/10.1186/1471-2288-2-5
_version_ 1782120195932815360
author O'Hagan, Anthony
Stevens, John W
author_facet O'Hagan, Anthony
Stevens, John W
author_sort O'Hagan, Anthony
collection PubMed
description BACKGROUND: The study of cost-effectiveness comparisons between competing medical interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences between the various approaches can be subtle, and one purpose of this article is to clarify some important distinctions. DISCUSSION: We discuss alternative measures in the framework of individual, patient-level, incremental net benefits. In particular we examine the probability of cost-effectiveness for an individual, proposed by Willan. SUMMARY: We argue that this is a useful addition to the range of cost-effectiveness measures, but will be of secondary interest to most decision makers. We also demonstrate that Willan's proposed estimate of this probability is logically flawed.
format Text
id pubmed-100784
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1007842002-04-04 The probability of cost-effectiveness O'Hagan, Anthony Stevens, John W BMC Med Res Methodol Debate BACKGROUND: The study of cost-effectiveness comparisons between competing medical interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences between the various approaches can be subtle, and one purpose of this article is to clarify some important distinctions. DISCUSSION: We discuss alternative measures in the framework of individual, patient-level, incremental net benefits. In particular we examine the probability of cost-effectiveness for an individual, proposed by Willan. SUMMARY: We argue that this is a useful addition to the range of cost-effectiveness measures, but will be of secondary interest to most decision makers. We also demonstrate that Willan's proposed estimate of this probability is logically flawed. BioMed Central 2002-03-11 /pmc/articles/PMC100784/ /pubmed/11914138 http://dx.doi.org/10.1186/1471-2288-2-5 Text en Copyright © 2002 O'Hagan and Stevens; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Debate
O'Hagan, Anthony
Stevens, John W
The probability of cost-effectiveness
title The probability of cost-effectiveness
title_full The probability of cost-effectiveness
title_fullStr The probability of cost-effectiveness
title_full_unstemmed The probability of cost-effectiveness
title_short The probability of cost-effectiveness
title_sort probability of cost-effectiveness
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC100784/
https://www.ncbi.nlm.nih.gov/pubmed/11914138
http://dx.doi.org/10.1186/1471-2288-2-5
work_keys_str_mv AT ohagananthony theprobabilityofcosteffectiveness
AT stevensjohnw theprobabilityofcosteffectiveness
AT ohagananthony probabilityofcosteffectiveness
AT stevensjohnw probabilityofcosteffectiveness